Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Nitazoxanide, approved for the treatment of Cryptosporidium parvum and Giardia lamblia, was found to inhibit hepatitis C virus replication.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur J Gastroenterol Hepatol

Title: European journal of gastroenterology & hepatology

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1473-5687

ISSN (Print): 0954-691X

Publication date (Electronic): Jan 2016

Volume: 28

Issue: 1

Affiliations

[1 ] Departments of aHepatology bClinical Biochemistry cPathology dEpidemiology, National Liver Institute, Menoufiya University, Menoufiya, Egypt.

Article

DOI: 10.1097/MEG.0000000000000492

PubMed ID: 26473300

SO-VID: f5d0b8c5-486e-4b8c-ad2a-a9400682c747

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by